Terazosin is an alpha-adrenergic blocker sold in the U.S. under 2 brand and generic names, for hypertension, prostatic hyperplasia and urinary retention. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
From the FDA label for Hytrin (application NDA019057). Other terazosin products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
If terazosin capsules administration is discontinued for several days, therapy should be reinstituted using the initial dosing regimen. Benign Prostatic Hyperplasia Initial Dose : 1 mg at bedtime is the starting dose for all patients, and this dose should not be exceeded as an initial dose. Patients should be closely followed during initial administration in order to minimize the risk of severe hypotensive response. Subsequent Doses : The dose should be increased in a stepwise fashion to 2 mg, 5 mg, or 10 mg once daily to achieve the desired improvement of symptoms and/or flow rates. Doses of 10 mg once daily are generally required for the clinical response. Therefore, treatment with 10 mg for a minimum of 4 to 6 weeks may be required to assess whether a beneficial response has been achieved. Some patients may not achieve a clinical response despite appropriate titration. Although some additional patients responded at a 20 mg daily dose, there was an insufficient number of patients studied to draw definitive conclusions about this dose. There are insufficient data to support the use of higher doses for those patients who show inadequate or no response to 20 mg daily. If terazosin administration is discontinued for several days or longer, therapy should be reinstituted using the initial dosing regimen. Use With Other Drugs : Caution should be observed when terazosin capsules…
Benign Prostatic Hyperplasia The incidence of treatment-emergent adverse events has been ascertained from clinical trials conducted worldwide. All adverse events reported during these trials were recorded as adverse reactions. The incidence rates presented below are based on combined data from six placebo-controlled trials involving once-a-day administration of terazosin at doses ranging from 1 to 20 mg. Table 1 summarizes those adverse events reported for patients in these trials when the incidence rate in the terazosin group was at least 1%, and was greater than that for the placebo group, or where the reaction is of clinical interest. Asthenia, postural hypotension, dizziness, somnolence, nasal congestion/rhinitis, and impotence were the only events that were significantly (p ≤ 0.05) more common in patients receiving terazosin than in patients receiving placebo. The incidence of urinary tract infection was significantly lower in the patients receiving terazosin than in patients receiving placebo. An analysis of the incidence rate of hypotensive adverse events (see PRECAUTIONS ) adjusted for the length of drug treatment has shown that the risk of the events is greatest during the initial seven days of treatment, but continues at all time intervals. TABLE 1. Adverse Reactions During Placebo-Controlled Trials Benign Prostatic Hyperplasia Body System Terazosin (N = 636) Placebo…
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
| # | Drug | Rating | Type | Form | Generic? | Typical price | |
|---|---|---|---|---|---|---|---|
| 1 | 72/100 | Prescription | Tablet | Generic | $4 | View → | |
| 2 | 72/100 | Prescription | Solution | Generic |
Imprint codes, colour and shape from the FDA’s labelling data. Match the imprint on your pill — or search any imprint.
| Imprint | Strength | Colour | Shape | Maker |
|---|---|---|---|---|
| TL383 | 1 mg | gray | capsule | — |
| AP783 | 5 mg | pink | capsule | — |
| AP784 | 10 mg | turquoise | capsule | — |
| AP781 | 1 mg | white | capsule | — |
| AP782 | 2 mg | yellow | capsule | — |
| TL384 | 2 mg | white |
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Terazosin capsules are contraindicated in patients known to be hypersensitive to terazosin hydrochloride.
In controlled trials, terazosin have been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: • analgesic/anti-inflammatory (e.g., acetaminophen, aspirin, codeine, ibuprofen, indomethacin); • antibiotics (e.g., erythromycin, trimethoprim and sulfamethoxazole); • anticholinergic/sympathomimetics (e.g., phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); • antigout (e.g., allopurinol); • antihistamines (e.g., chlorpheniramine); • cardiovascular agents (e.g., atenolol, hydrochlorothiazide, methyclothiazide, propranolol); • corticosteroids; • gastrointestinal agents (e.g., antacids); • hypoglycemics; • sedatives and tranquilizers (e.g., diazepam).
| $4 |
| View → |
| capsule |
| — |
| TL383 | 1 mg | gray | capsule | — |
|---|
| TL384 | 2 mg | white | capsule | — |
|---|
| TL385 | 5 mg | orange | capsule | — |
|---|
| TL386 | 10 mg | green | capsule | — |
|---|
| TL383 | 1 mg | gray | capsule | — |
|---|